> Ablynx dosed the first patient in a Japanese phase 2a trial of its treatment for respiratory syncytial virus. Data from the study are due in the second half of next year. Release
> MyBiotics entered into another licensing agreement with Ferring. The deal covers microbiome therapies. Statement
> Artios Pharma in-licensed a DNA nuclease-targeting cancer drug. The asset is the first picked up by Artios through its research collaboration with Masaryk University in the Czech Republic. Release
> A phase 2 trial of Sanfit’s treatment of calciphylaxis met its primary and secondary endpoints. The finding suggests SNF472 may aid wound healing and reduce pain in patients with the rare disease. Statement
> BioMedPartners closed a CHF 100 million ($106 million) investment fund. The Swiss VC shop will use the money to back 12 to 15 early to midstage companies in its home country and neighboring nations. Release (PDF)
> Summit Therapeutics expanded enrollment in its phase 2 Duchenne muscular dystrophy trial. Enrollment is now open to patients who participated in the phase 1 study but fell foul of the more restrictive inclusion/exclusion criteria of the subsequent trial. Statement